Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2026 | The potential value of broad rim lesions in the understanding and management of multiple sclerosis

Joost Smolders, MD, PhD, Erasmus University Medical Center, Rotterdam, Netherlands, discusses the potential value of broad rim lesions in the understanding and management of multiple sclerosis. Dr Smolders highlights that these lesions could help to stratify patients for trials and inform treatment decisions. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

Well, I think the past years the field really discovered a lot of things that helped to explain the heterogeneity in people with multiple sclerosis. For instance, if you look at MRI data, you know, we used to look at the presence of T2 hyper-intense lesions and now we look with a far more granular view at these MRI images. And if we look at white matter lesions, we can now identify paramagnetic rim lesions...

Well, I think the past years the field really discovered a lot of things that helped to explain the heterogeneity in people with multiple sclerosis. For instance, if you look at MRI data, you know, we used to look at the presence of T2 hyper-intense lesions and now we look with a far more granular view at these MRI images. And if we look at white matter lesions, we can now identify paramagnetic rim lesions. We can identify slowly expanding lesions. And I think, you know, if we can image correlates of broad rim lesions also on MR imaging, this could further improve our understanding of what progression in MS is and how you can capture this with regular imaging strategies in our patients. So it can really help to stratify our patients for trials, for maybe also therapies targeting progression in the future. I think there’s a lot we can learn from it.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...